Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genzyme reorganization?

Executive Summary

Genzyme CEO Henri Termeer was asked several times during April 16 conference call about the company's capital structure in light of recent concerns about tracking stocks and corporate accounting. "We are always looking at the capital structure of the company. We are doing that now and will be looking at doing that in the future," Termeer says. Pressed for further comment, Termeer says, "this is an earnings call, not a structure call"...

You may also be interested in...

Genzyme ends tracking-stock structure

Genzyme will exchange shares of Genzyme Biosurgery stock and Genzyme Molecular Oncology stock for shares of Genzyme General stock on June 30. "We do not expect to make any major changes within our business or research programs at this time," CEO Henri Termeer says. Termeer was asked about the company's capital structure in light of concerns about tracking stocks and corporate accounting during an April 16 earnings call (1"The Pink Sheet" April 28, In Brief)...

DJO Thinks Trilliant Is Brilliant, Announces Acquisition

DJO Global will buy Trilliant Surgical to further its ongoing expansion into the US foot and ankle market.

Legend Biotech CEO Ying Huang On Moving Fast In the BCMA CAR-T Race

Ying Huang was named CEO as his predecessor came under investigation in China and as partner Janssen was getting closer to seeking US FDA approval for its lead CAR-T therapy.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts